Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma

We investigated whether genomic scar signatures associated with homologous recombination deficiency (hrd), which include telomeric allelic imbalance (tai), large-scale transition (lst), and loss of heterozygosity (loh), can predict clinical outcomes in patients with ovarian clear cell carcinoma (occc). we enrolled patients with occc (n = 80) and high-grade serous carcinoma (hgsc; n = 92) subjected to primary cytoreductive surgery, most of whom received platinum-based adjuvant chemotherapy. genomic scar signatures based on genome-wide copy number data were determined in all participants and investigated in relation to prognosis. occc had significantly lower genomic scar signature scores than hgsc (p < 0.001). near-triploid occc specimens showed higher tai and lst scores compared with diploid tumors (p < 0.001). while high scores of these genomic scar signatures were significantly associated with better clinical outcomes in patients with hgsc, the opposite was evident for occc. multivariate survival analysis in patients with occc identified high loh scores as the main independent adverse predictor for both cancer-specific (hazard ratio [hr] = 3.22, p = 0.005) and progression-free survival (hr = 2.54, p = 0.01). in conclusion, genomic scar signatures associated with hrd predict adverse clinical outcomes in patients with occc. the loh score was identified as the strongest prognostic indicator in this patient group.